Andrea Armani

Prof. Andrea Armani

Department of Human Sciences and Promotion of the Quality of Life, San Raffaele University of Rome, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2019 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
Marco InfanteMarco Infante
Marco Infante
EME. Moriconi
E. Moriconi
AAAndrea Armani
Andrea Armani
AFA. Fabbri
A. Fabbri
GMG. Mantovani
G. Mantovani
CSChiara Simeoli
Chiara Simeoli

7 May 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
AAAndrea Armani
Andrea Armani
FCFrancesca Cinti
Francesca Cinti
VMVincenzo Marzolla
Vincenzo Marzolla
JMJames Morgan
James Morgan
GCGreg A. Cranston
Greg A. Cranston
Massimiliano CaprioMassimiliano Caprio
Massimiliano Caprio
The mineralocorticoid receptor (MR) controls adipocyte function, but its role in the conversion of white adipose tissue (WAT) into thermogenic fat has not been elucidated. We investigated responses to the MR antagonists spironolactone (spiro; 20 mg/kg/d) and drospirenone (DRSP; 6 mg/kg/d) in C57BL/6 mice fed a high‐fat (HF) diet for 90 d. DRSP and spiro curbed HF diet‐induced impairment in glucose tolerance, and prevented body weight gain and white fat expansion. Notably, either MR antagonist induced up‐regulation of brown adipocyte‐specific transcripts and markedly increased protein levels of uncoupling protein 1 (UCP1) in visceral and inguinal fat depots when compared with the HF diet group. Positron emission tomography and magnetic resonance spectroscopy confirmed acquisition of brown fat features in WAT. Interestingly, MR antagonists markedly reduced the autophagic rate both in murine preadipocytes in vitro (10 ‐5 M) and in WAT depots in vivo , with a concomitant increase in UCP1 protein expression. Moreover, the autophagy repressor bafilomycin A1 (10 ‐8 M) mimicked the effect of MR antagonists, increasing UCP1 protein expression in primary preadipocytes. Hence, we showed that adipocyte MR regulates brown remodeling of WAT through a modulation of autophagy. These results provide a rationale for the use of MR antagonists to prevent the adverse metabolic consequences of adipocyte dysfunction.—Armani, A., Cinti, F., Marzolla, V., Morgan, J., Cranston, G. A., Antelmi, A., Carpinelli, G., Canese, R., Pagotto, U., Quarta, C., Malorni, W., Matarrese, P., Marconi, M., Fabbri, A., Rosano, G., Cinti, S., Young, M. J., Caprio, M. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high‐fat‐diet‐fed mice. FASEB J. 28, 3745–3757 (2014). www.fasebj.org

21 April 2010 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
AAAndrea Armani
Andrea Armani
CMCaterina Mammi
Caterina Mammi
VMVincenzo Marzolla
Vincenzo Marzolla
MCMatilde Calanchini
Matilde Calanchini
AAAntonella Antelmi
Antonella Antelmi
Massimiliano CaprioMassimiliano Caprio
Massimiliano Caprio

1 April 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
VMVincenzo Marzolla
Vincenzo Marzolla
AAAndrea Armani
Andrea Armani
CMCaterina Mammi
Caterina Mammi
MMM. Elizabeth Moss
M. Elizabeth Moss
VPVittoria Pagliarini
Vittoria Pagliarini
Massimiliano CaprioMassimiliano Caprio
Massimiliano Caprio

1 March 2012 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
VMVincenzo Marzolla
Vincenzo Marzolla
AAAndrea Armani
Andrea Armani
MZMaria-Christina Zennaro
Maria-Christina Zennaro
FCFrancesca Cinti
Francesca Cinti
CMCaterina Mammi
Caterina Mammi
Massimiliano CaprioMassimiliano Caprio
Massimiliano Caprio

23 January 2013 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AMAdam P. McGraw
Adam P. McGraw
JBJessamyn Bagley
Jessamyn Bagley
WCWei‐Sheng Chen
Wei‐Sheng Chen
CGCarol Galayda
Carol Galayda
HNHeather Nickerson
Heather Nickerson
IJIris Z. Jaffe
Iris Z. Jaffe
Background: Aldosterone levels correlate with the incidence of myocardial infarction and mortality in cardiovascular patients. Aldosterone promotes atherosclerosis in animal models, but the mechanisms are poorly understood. Methods and Results: Aldosterone was infused to achieve pathologically relevant levels that did not increase blood pressure in the atherosclerosis‐prone apolipoprotein E–knockout mouse (ApoE−/−). Aldosterone increased atherosclerosis in the aortic root 1.8±0.1‐fold after 4 weeks and in the aortic arch 3.7±0.2‐fold after 8 weeks, without significantly affecting plaque size in the abdominal aorta or traditional cardiac risk factors. Aldosterone treatment increased lipid content of plaques (2.1±0.2‐fold) and inflammatory cell content (2.2±0.3‐fold), induced early T‐cell (2.9±0.3‐fold) and monocyte (2.3±0.3‐fold) infiltration into atherosclerosis‐prone vascular regions, and enhanced systemic inflammation with increased spleen weight (1.52±0.06‐fold) and the circulating cytokine RANTES (regulated and normal T cell secreted; 1.6±0.1‐fold). To explore the mechanism, 7 genes were examined for aldosterone regulation in the ApoE−/− aorta. Further studies focused on the proinflammatory placental growth factor (Pl GF ), which was released from aldosterone‐treated ApoE−/− vessels. Activation of the mineralocorticoid receptor by aldosterone in human coronary artery smooth muscle cells ( SMC s) caused the release of factors that promote monocyte chemotaxis, which was inhibited by blocking monocyte Pl GF receptors. Furthermore, Pl GF ‐deficient ApoE−/− mice were resistant to early aldosterone‐induced increases in plaque burden and inflammation. Conclusions: Aldosterone increases early atherosclerosis in regions of turbulent blood flow and promotes an inflammatory plaque phenotype that is associated with rupture in humans. The mechanism may involve SMC release of soluble factors that recruit activated leukocytes to the vessel wall via Pl GF signaling. These findings identify a novel mechanism and potential treatment target for aldosterone‐induced ischemia in humans.